Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs

2020-05-14T12:01:00Z (GMT) by Anatoly Chernyshev
An essential overview of the biological role of coronavirus viroporin (envelope protein) is given, together with the effect of its known inhibitors on the life cycle of coronavirus. A docking study is conducted using a set of known drugs approved worldwide (ca. 6000 compounds) on a structure of the SARS-CoV-2 viroporin modelled from the published NMR-resolved structures. The screening has identified 36 promising drugs currently on the market, which could be proposed for pre-clinical trials.